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effect on T-cell subsets.Table 1
Risk Factor and IDO Activity Correlations for GVHD
Clinical Characteristics and GVHD
Risk Factors
GVHD
(n¼ 13)
No GVHD
(n ¼7)
P value
Age at HSCT, median (range) years 20 (2-69) 31 (1-49) 1.000*
Malignant disease, n (%) 10 (76.9) 7 (100.0) 0.521#
Non-malignant disease, n (%) 3 (23.1) 0
Malignant Disease Status at HSCT
CR1 3 (23.1) 3 (42.9) 0.415#
CR2 4 (30.8) 1 (14.3)
Active/Refractory 3 (23.1) 3 (42.9)
Conditioning Regimen
Myeloablative 7 (53.8) 5 (71.4) 0.484#
Reduced-intensity 6 (46.2) 2 (28.6)
HSCT Product
Bone marrow 6 (46.2) 1 (14.3) 0.199#
Peripheral Blood 5 (38.5) 3 (42.9)
Umbilical cord blood 2 (15.3) 3 (42.9)
HLA-Mismatch
0 9 (69.2) 4 (57.1) 0.207#
1 4 (30.8) 1 (14.3)
2 0 2 (28.6)
Unrelated Donor 9 (69.2) 5 (71.4) 1.000#
CD34+ cells/kg dose 3.63 x 106 3.19 x 106 0.757*
TNC cells/kg dose 4.81 x 108 4.18 x 108 0.699*
Post-HSCT Disease Relapse, n (%) 6 (46.2) 2 (28.6) 0.642#
Kyn/Trp (IDO) Ratio, median
(range)
1.55
(0.41-
15.15)
0.69
(0.16-2.06)
0.027*
AUC (Kyn/Trp IDO Ratio), median
(range)
43.20
(6.10-
666.80)
11.76
(8.03-35.49)
0.007*458
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Background: Grip strength and 2 minute walk test have
been suggested as elements of chronic graft-vs-host disease
(GVHD) assessment in clinical trials.
Methods: Using all available data (n¼584, 1,689 follow-up
visits, total of 2,273 visits) from a prospective observational
cohort study, we explored the relationship between grip
strength and 2 minute walk test and patient-reported
outcomes (Lee symptomscale, SF-36 and FACT-BMTquality of
life instruments, andHuman Activity Proﬁle, or HAP), chronic
GVHD severity (NIH global 0-3 score, clinician global 0-3
score, and patient-reported global 0-3 score) and mortality
(overall survival (OS) and non-relapse mortality (NRM)) in
multivariate analyses adjusted for signiﬁcant covariates.
Results: In multivariate analysis, 2 minute walk test was
signiﬁcantly ( P < .001) associated with intuitive domains of
the Lee Symptom Scale (overall, skin, lung, energy), while
grip strength was not. Excepting MCS (mental component
score), 2 minute walk test had signiﬁcant associationwith all
studied SF-36 domain and summary scores ( P < .001) and
FACT summary and domain scores ( P < .001). Both grip
strength and 2 minute walk test had signiﬁcant association
with FACT summary scores and HAP (maximum activity
score (MAS), and adjusted activity score (AAS)). In univariate
analysis using all visit data, 2minutewalk test had signiﬁcant
association with global chronic GVHD severity, as calculated
from organ scores, reported by clinicians, and reported by
patients ( P < .01). Patients with NIH global score of mild or
less and moderate achieved on average 20.7 and 15.3 feet,
respectively, greater distance covered compared to those
with NIH severe chronic GVHD. Conversely, grip strength had
no signiﬁcant association with any of these measures of
chronic GVHD. In time-varying multivariate models exam-
ining all data and adjusting for signiﬁcant covariates, 2
minute walk test was signiﬁcantly associated with both OS
and NRM (both P < .001), while no association was found for
grip strength.
Conclusions: Based on its consistent association with
symptom burden, QOL, chronic GVHD severity andmortality,
these data support the 2 minute walk test as a useful
measure in chronic GVHD assessment.459
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Background: Indoleamine 2,3-dioxygenase (IDO), the rate
limiting enzyme of tryptophan metabolism, in part mediates
allogeneic tolerance and may be important in allogeneic
HSCTand GVHD.
Objective: To prospectively evaluate in vivo IDO activity in
allogeneic HSCT recipients and test our hypothesis that IDO
activity is associated with acute GVHD.
Methods: Patients (>1 year-old) receiving allogeneic HSCT
were eligible. Plasma samples were collected at baseline and
days -3, 0, +7, 14, 21, 30, 45, 60, 100, 180, and 365 relative to
HSCT for tryptophan (Trp) and kynurenine (Kyn) quantiﬁca-
tion (mM) by high performance liquid chromatography.
Mann-Whitney rank tests were used to test associations
betweenKyn/Trp ratio (IDO activity) and area under the curve
(AUC) Kyn/Trp ratio and GVHD. Potential confounders were
tested for associationwith GVHDusing Fisher's exact tests (#)
or Mann-Whitney rank tests (*). Analyses were performed
using R (ver 2.12.1) and GraphPad Prism (ver 5.04).
Results: Twenty patients were evaluable for IDO activity and
GVHD. AMLwas themost common diagnosis (n¼ 9, 45%). All
patients engrafted atmean (SD) 17.2 (+/- 5) days. Acute GVHD
occurred in 13 (59.1%) patients: 10 were Grade I-II and 3were
Grade III.Median time toGVHDdiagnosiswas 46 days. Table 1
